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he lack of adherence to pre-
scribed therapy is a major
issue in patients with kidney dis-
ease. For instance, non-adherence
occurs in a significant proportion
of patients with resistant hyperten-
sion with or without chronic kid-
ney disease (CKD).1,2 In dialysis
patients, the lack of adherence also
explains an uncontrolled hyper-
phosphatemia and hyperparathy-
roidism.1,3 In renal transplantation,
non-adherence to immunosuppres-
sive therapies can lead to serious
complications, such as acute rejec-
tion and graft loss.4 Studying and
understanding non-adherence is
thus of importance. Different fac-
tors are known to be associated
with non-adherence. Among them,
pill burden and polypharmacy are
well-identified risk factors.1 The
issue of pill burden is well illus-
trated in the study by Marienne
et al.5 in this issue. Of interest,
the authors studied pill burden
before and until 1 year after renal
transplantation. In this retrospec-Correspondence: Pierre Delanaye, Service
de Dialyse, CHU Sart Tilman, 4000 Liège,
Belgium. E-mail: pierre_delanaye@yahoo.fr
Kidney International Reports (2021) 6, 5–6tive study, the same patients from
1 center in France were followed
before and after transplantation. A
comparison with the French regis-
try of dialysis and transplantation
showed that the patients included
were representative of the CKD
population in that country.
In addition to the pill burden, the
authors also studied the complexity
of the treatment, based on a recog-
nized score, the Medication Regimen
Complexity Index. This score varies
with the number of drugs prescribed
and is based on 3 components:
dosage form or administration route,
dosing frequency, and additional
instructions concerning administra-
tion. The authors convincingly show
that both the pill burden and the
complexity of the treatment are
higher after than before trans-
plantation. Also, the authors clearly
show that the class of drugs varies
from dialysis to transplantation
(immunosuppressive drugs be-
coming the first class of drug after
transplantation). The study remains,
however, descriptive, and we do not
know whether this higher pill
burden or complexitywill lead to the
same degree of non-adherence in5
patients before and after trans-
plantation. The perception of the
patient (but also of the physician)
regarding the relevance of the drug
is probably important but is difficult
to capture in the context of a retro-
spective study.1
The perception of the impor-
tance of the drug can be easily
illustrated by some examples in
which both the patient and the
physician will be involved.
Indeed, one could reasonably hy-
pothesize that, at the same level of
complexity, adherence to immu-
nosuppressive drugs is higher in a
transplant recipient than adher-
ence to phosphate binders when
the same patient was undergoing
dialysis. Immunosuppressive
drugs are certainly considered
essential to the patients who will
keep in mind the risk of returning
to dialysis, whereas phosphate
binders are prescribed to control
hyperphosphatemia, which will
have very few direct impacts on
patients’ symptoms. In addition,
the physician will surely explain
(and insist on) the risk of non-
adherence to immunosuppression
to their patients, probably in a
more intense manner than the risk
of phosphate binding, for which a
definitive evidence of efficacy on
clinically relevant outcomes is still
lacking. Regardless of the shared
perception between physicians
and patients, it remains likely that
decreasing the pill burden and the
complexity of treatment could
certainly help to improve adher-
ence of the patients (even if
strictly speaking the impact of
decreasing complexity on adher-
ence still needs to be proven). As
reminded by the authors, a strat-
egy of “polypills” is interesting
(even if not always easy to
implement), as is a strategy of
“deprescribing.”
COMMENTARY P Delanaye and C Mariat: AdherenceThe potential role of education,
social support, or both, and the
intervention of pharmacists dedi-
cated to patients with CKD are
probably also of interest in all as-
pects of our specialty.6,7 Other
straightforward ideas deserved to
be explored. First, the concept of
medication reconciliation must not
be neglected. Albeit obvious and
fundamental with regard to medi-
cation safety, the notion of medi-
cation reconciliation has been well
shown to be insufficient in patients
with complex conditions such as
CKD, especially during care transi-
tions. Medication conciliation is al-
ways the first step to improve
adherence to therapies.8 Likewise,
in dialysis patients, the directly
observed therapy—that is, a drug
given directly by the nurse during
the dialysis session—should be
promoted when possible. We have
shown, for example, that directly
observed therapy with native
vitamin D (cholecalciferol, 25,000
units once a week) was associated
with better vitamin D 25-OH con-
centrations. In the same context,
therapies dedicated to the treatment
of secondary hyperparathyroidism
can be prescribed orally for home
use or orally or intravenously dur-
ing the dialysis session (calcitriol or
either cinacalcet or etelcalcetide).
The better results obtained in the6
real life with intermittent therapies
is due, at least in part, to the better
adherence associated with a
directly observed therapy strategy.
In transplantation, simple strategies
can help to improve adherence
—for example, health apps on
smartphones, which have been
shown to reduce variability in
tacrolimus trough concentrations.9
Although improving adherence
to drug regimens by patients with
CKD remains a true and important
challenge, the mechanisms under-
lying adherence and the impact of
specific interventions still need to
be further clarified.DISCLOSURE
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